Evolving role of tissue factor and its pathway inhibitor

被引:43
作者
Doshi, SN [1 ]
Marmur, JD [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA
关键词
atherosclerosis; sepsis; tissue factor; tissue factor pathway inhibitor;
D O I
10.1097/00003246-200205001-00012
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To review the experimental and clinical evidence of the emerging role of tissue factor in intravascular thrombosis and to examine evidence supporting the potential use of tissue factor pathway inhibitor as an antithrombotic therapeutic agent. Data Sources and Study Selection: A PubMed search was conducted encompassing articles in the English language relating to tissue factor and tissue factor pathway inhibitor in intravascular coagulation. Conclusions: Tissue factor, a membrane-bound procoagulant glycoprotein, is the initiator of the extrinsic clotting cascade, which is the predominant coagulation pathway in vivo. The traditional view localizes tissue factor to extravascular sites, where it remains sequestered from circulating factor VII until vascular integrity is disrupted or until tissue factor expression is induced in endothelial cells or monocytes. This perspective has been challenged since the discovery of tissue factor antigen in plasma, on circulating microparticles, and on leukocytes in whole blood. Recently, the apparent role of tissue factor has expanded with the demonstration that this molecule also functions as a signaling receptor, Recombinant tissue factor pathway inhibitor, an analogue of the physiologic inhibitor of tissue factor, is a potent inhibitor of thrombus formation in experimental models. In summary, the tissue factor pathway initiates thrombosis in vivo. In addition to its classic tissue-bound distribution, recently discovered blood-borne tissue factor may have an important procoagulant function. Despite showing promise in early human studies, a recently completed phase 3 trial of recombinant tissue factor pathway inhibitor in severe sepsis failed to show a reduction in the primary end point of 28-day all-cause mortality. Tissue factor pathway inhibitor, however, remains a plausible therapeutic agent in other conditions of increased thrombogenicity, such as acute coronary syndromes, and further studies to examine this potential are warranted.
引用
收藏
页码:S241 / S250
页数:10
相关论文
共 132 条
  • [1] ABILDGAARD U, 1992, ADV EXP MED BIOL, V313, P199
  • [2] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
    Abraham, E
    Reinhart, K
    Svoboda, P
    Seibert, A
    Olthoff, D
    Dal Nogare, A
    Postier, R
    Hempelmann, G
    Butler, T
    Martin, E
    Zwingelstein, C
    Percell, S
    Shu, V
    Leighton, A
    Creasey, AA
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (11) : 2081 - 2089
  • [3] Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review
    Vincent, JL
    Abraham, E
    Esmon, C
    Hack, CE
    [J]. CRITICAL CARE MEDICINE, 2000, 28 (09) : S33 - S33
  • [4] The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
    Amengual, O
    Atsumi, T
    Khamashta, MA
    Hughes, GRV
    [J]. THROMBOSIS AND HAEMOSTASIS, 1998, 79 (02) : 276 - 281
  • [5] AMERI A, 1992, BLOOD, V79, P3219
  • [6] DIFFERENTIAL EXPRESSION OF TISSUE FACTOR PROTEIN IN DIRECTIONAL ATHERECTOMY SPECIMENS FROM PATIENTS WITH STABLE AND UNSTABLE CORONARY SYNDROMES
    ANNEX, BH
    DENNING, SM
    CHANNON, KM
    SKETCH, MH
    STACK, RS
    MORRISSEY, JH
    PETERS, KG
    [J]. CIRCULATION, 1995, 91 (03) : 619 - 622
  • [7] Tissue factor in human coronary atherosclerotic plaques
    Ardissino, D
    Merlini, PA
    Arlens, R
    Coppola, R
    Bramucci, E
    Lucreziotti, S
    Repetto, A
    Fetiveau, R
    Mannucci, PM
    [J]. CLINICA CHIMICA ACTA, 2000, 291 (02) : 235 - 240
  • [8] Tissue-factor antigen and activity in human coronary atherosclerotic plaques
    Ardissino, D
    Merlini, PA
    Ariens, R
    Coppola, R
    Bramucci, E
    Mannucci, PM
    [J]. LANCET, 1997, 349 (9054) : 769 - 771
  • [9] Thrombogenic potential of human coronary atherosclerotic plaques
    Ardissino, D
    Merlini, PA
    Bauer, KA
    Bramucci, E
    Ferrario, M
    Coppola, R
    Fetiveau, R
    Lucreziotti, S
    Rosenberg, RD
    Mannucci, PM
    [J]. BLOOD, 2001, 98 (09) : 2726 - 2729
  • [10] STRUCTURALLY DISTINCT PLASMA-MEMBRANE REGIONS GIVE RISE TO EXTRACELLULAR MEMBRANE-VESICLES IN NORMAL AND TRANSFORMED LYMPHOCYTES
    ARMSTRONG, MJ
    STORCH, J
    DAINIAK, N
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 946 (01) : 106 - 112